In this discussion, Kenneth Anderson, MD, Dana-Farber Cancer Institute, Boston, MA, Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, and Simon Harrison, MBBS, MRCP(UK), FRCPath(UK), FRACP, PhD, Peter MacCallum Cancer Centre, Melbourne, Australia, share insights into a session focused on recent advances in high-risk multiple myeloma (HRMM). The experts touch on genomic drivers involved in high-risk disease, the importance of the tumor microenvironment, the new definition of HRMM, and more. This discussion took place at the 1st International Workshop on High-Risk Multiple Myeloma (iw
